Jefferies maintains Buy on Nurix Therapeutics, raises target to $45
Jefferies analyst Roger Song maintained a Buy rating on Nurix Therapeutics and raised the price target to $45 from $41, indicating a positive outlook on the stock.
*this image is generated using AI for illustrative purposes only.
Jefferies analyst Roger Song has maintained a Buy rating on Nurix Therapeutics, citing an updated valuation. The firm increased the price target for the stock to $45, up from the previous target of $41.
Rating and Target Details
The revised price target reflects a more optimistic outlook on the company's performance. The decision to retain the Buy rating suggests confidence in the stock's potential to deliver returns above the market average.
| Metric | Value |
|---|---|
| Rating | Buy |
| Previous Price Target | $41 |
| New Price Target | $45 |
The adjustment comes as the analyst evaluates the company's current market position and future growth prospects.
What specific catalysts or data readouts are expected to drive the stock toward the new $45 price target?
How does Nurix Therapeutics' current pipeline progress compare to its competitors in the targeted therapy space?
What are the potential risks or market headwinds that could prevent the company from meeting this revised valuation?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
